Abstract: The invention relates to compounds of the formula 1 R1—O—(A—O)x—(CH2)y—R2  (1) in which R1 is branched or straight-chain C4-C30-alkyl, C4-C30-alkenyl or C4-C30-alkylaryl, A is C2-C4-alkylene, x is an integer from 1 to 100, y is 1, 2, 3 or 4 and R2 is a radical selected from structures of the formulae 2 and 3 —CO—NR3R4  (2) in which one of the radicals R3 and R4 is a hydrocarbon chain which has at least one free NH or NH2 group and the other radical is hydrogen or a hydrocarbon chain which has at least one free NH or NH2 group and R5 is hydrogen or a hydrocarbon chain which has at least one free NH or NH2 group.

Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing depression in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer.

Abstract: The Invention relates to a process for the preparation of a compound of the formula wherein Q, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, which comprises a) reacting a compound of the formula  with a halogenating agent to form a compound of the formula b) converting a compound of formula (II) by means of a halogenating agent into a compound of the formula  optionally c) converting the compound of formula (IV) into a compound of formula (III); d) converting a compound of formula (III) by means of a compound of the formula e) converting a compound (IV) by means of a compound (V) into a compound (VI); and f) converting a compound (VI) by means of a chlorinating agent into a compound (I); a compound (IV); to a process for the preparation of a compound (III) and to a process for the preparation of a compound (IV).

Abstract: The invention relates to compounds of the formula (I), in which the symbols have the following meaning: R(1) is 1. alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; 2. alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, in which one to all hydrogen atoms are replaced by fluorine; 3. alkenyl having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms; or 4. —CnH2n−nn—Y, nn is zero or 2; and n is zero, 1, 2, 3 or 4; where n is unequal to zero or 1 if nn is equal to 2; 5. —CnH2n−nn—Y, nn is zero or 2; and n is 1, 2, 3 or 4; where n is unequal to 1 if nn is equal to 2.

Abstract: Crystals with an average crystal size of ≦10 &mgr;m comprising compounds of the formula Ia and/or IIa A process for making said crystals.

Abstract: The invention relates to compounds of formula (I), wherein the symbols have the meanings indicated in the specification. The inventive compounds exhibit dramatic antiarrhythmic proprieties and contain a cardioprotective compound. They can preventively inhibit or strongly reduce pathophysiologic processes upon occurrence of ischemic injuries, especially ischemic cardiac arrhythmia. Said compounds also exhibit a strong inhibiting effect on cellular proliferation.

Abstract: The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.

Abstract: Tetrazolyl-phenyl acetamides are active as glucokinase activators, and are able to increase insulin secretion, which makes them useful for treating type II diabetes.

Abstract: Method of treating warm blooded animals suffering from psychotic disorders. The method includes administering a pharmaceutically effective amount of sustained-release microparticles that include risperidone, or a pharmaceutically acceptable acid addition salt thereof, and a biodegradable and biocompatible polymeric matrix.

Abstract: A process for preparing enantiomerically enriched tetrahydrobenzothipeine oxides comprises cyclizing an enantiomerically enriched aryl-3-propanalsulfoxide wherein the sulfur atom of the aryl-3-propanalsulfoxide is a chiral center.

Abstract: The present invention relates to methods for preparing 2,2-dimethyl-5-acyloxy-10-propyl-2H,8H-benzo[1,2-b:3,4-b′]dipyran-8-one (5) and 2,2-dimethyl-5-hydroxy-10-propyl-2H,8H-benzo[1,2-b:3,4-b′]dipyran-8-one (6) and their use as intermediates for the synthesis of antiviral calanolide compounds. For example, Fries rearrangement on compound 5 or Friedel-Crafts reaction on 6, yields intermediate 2,2-dimethyl-5-hydroxy-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b′]dipyran-8-one (4), which, in turn, can be converted to (+)-calanolide A and (−)-calanolide B. The coupling of compound 6 with the appropriate chiral molecule under Mitsunobu or nucleophilic displacement leads to the asymmetric synthesis of antiviral calanolide compounds.

Abstract: The invention concerns a compound of the formula (I): wherein, for example: R1 is of the formula —NHC(═O)Rb wherein Rb is, for example, (1-4C)alkyl; R2 and R3 are hydrogen or fluoro; R2 and R3 are hydrogen or fluoro; D is O; R4 and R5 are hydrogen, (1-4C)alkyl or AR-oxymethyl; AR is phenyl or phenyl(1-4C)alkyl; R6 is hydrogen; >A—B— is of the formula >C═C(Ra)—, >CHCHRa—, or >C(OH)CHRa— (> represents two single bonds) wherein Ra is hydrogen or (1-4C)alkyl; and pharmaceutically-acceptable salts thereof; processes for their preparation; pharmaceutical compositions containing them and their use as antibacterial agents.

Abstract: This invention relates to an organomercapto Au(I) complex having the formula [(M—SOL)n—A—S—Au—S—A—(SOL—M)n]M wherein M is a cationic counterion; SOL is a solubilizing group: A is a substituted or unsubstituted divalent organic linking group; and n is 1 to 4 and wherein the compound is symmetrical. It further relates to a method of manufacturing an organomercapto Au(I) complex comprising reacting an Au (I) complex with an organomercapto ligand and isolating the resulting organomercapto Au(I) complex from the reaction mixture.

Abstract: The invention relates to pesticidal trifluoromethylpyrrolcarboxamides of formula I wherein R1 is hydrogen, halogen, C1-4haloalkyl or C1-4alkyl, R2 is C1-4alkyl, C1-4haloalkyl, C1-4alkoxy-C1-4alkyl, cyano, C1-4alkylsulfonyl, phenylsulfonyl, di(C1-4alkyl)aminosulfonyl, C1-6alkylcarbonyl, benzoyl, or substituted phenylsulfonyl or benzoyl, and A is a group wherein R3 is C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6haloalkenyl, C2-6alkinyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkenyloxy, C2-6haloalkenyloxy, C2-6alkinyloxy, C3-7cycloalkyl, C1-4alkyl-C3-7cycloalkyl, C4-7cycloalkenyl, C1-4alkyl-C4-7cycloalkenyl, C3-7cycloalkyloxy, C1-4alkyl-C3-7cycloalkyloxy, C5-7cycloalkenyloxy, C1-4alkyl-C5-7cycloalkenyloxy, phenyl, naphthyl, phenoxy, naphthyloxy, or substituted phenyl or phenoxy wherein the substitutents are one to three groups independently selected from halogen, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, cyano, C1-4alkoxycarbonyl, C1-4alkylcarbonyl, C1-4haloalkyl, C1-4haloalkoxy, met

Abstract: The invention provides a urokinase production inhibitor or angiogenesis inhibitor comprising as an active component an ozonide derivative represented by the formula (1), and method of prevention or therapy using the inhibitor wherein A is an oxygen atom or N—R (wherein R is phenyl or phenyl having as a substituent lower alkyl having 1 to 6 carbon atoms, lower alkoxyl having 1 to 6 carbon atoms or a halogen atom); B is an oxo group or —R4; and (1) when A is an oxygen atom, R1 is a hydrogen atom, etc., R2 is phenyl, etc., R3 is a hydrogen atom, etc., B is an oxo group or —R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.; (2) when A is N—R, R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., R3 is a hydrogen atom, etc., B is —R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.

Abstract: Provided are a novel ammonium (3R,5S)-3,5,6-trihydroxyhexanoate derivative represented by the following formula (I): wherein R1 represents a benzyl group which may have a substituent, a triphenylmethyl group which may have a substituent, an organosilyl group or a C1-5 acyl group; and A means a specific amine; and a preparation process of the derivative.

Abstract: A naphthalene derivative, binaphthalene derivative and biphenyl derivative, all having an oxetane group, capable of being cationically polymerized and a cationically curable compound containing a naphthalene derivative having an oxetanyl group and an aromatic compound having an epoxy group or an oxetanyl group.

Abstract: A phthalimide represented by general formula (I): wherein L represents L-1 or L-2: (wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, etc.); A represents an oxygen atom, a sulfur atom or —NR5— (wherein R5 is a hydrogen atom, an alkyl group, an alkenyl group, etc.); R represents a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, a phenyl group, etc.; X represents a halogen atom; Y represents a hydrogen atom or a halogen atom; and Z represents a hydrogen atom, an alkyl group, a haloalkyl group or a halogen atom. The compound exhibits excellent herbicidal effects with high selectivity.

Abstract: In a process for preparing phthalic anhydride by catalytic gas-phase oxidation of o-xylene/naphthalene mixtures by molecular oxygen, use is made of a catalyst I in a first zone on the gas inlet side which makes up from 25 to 75 percent by volume of the total catalyst volume, comprising, in each case based on the catalytically active composition, from 1 to 10% by weight of vanadium oxide (calculated as V205), from 1 to 10% by weight of antimony oxide (calculated as Sb203) and from 80 to 98% by weight of titanium dioxide of the anatase type having a BET surface area of from 13 to 28 m2/g and also from 0.

Abstract: The present invention relates to novel triazole compounds of the following formula: wherein R1 to R5 have the meanings provided herein. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing triazole compounds.